<p>Drug makers Sun Pharma and Hetero are recalling products in the US market for manufacturing issues, according to the US Food and Drug Administration (USFDA).</p>.<p>As per the US health regulator's latest Enforcement Report, the US-based arm of Sun Pharmaceutical Industries is recalling a generic drug indicated to raise blood pressure in adult patients with acute hypotension.</p>.<p>Princeton (New Jersey) based Sun Pharmaceutical Inc is recalling 16,450 vials of Norepinephrine Bitartrate Injection for "Failed Impurities/Degradation Specifications", it said.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/cost-of-651-essential-medicines-down-7-from-april-as-govt-caps-ceiling-prices-1206280.html" target="_blank">Cost of 651 essential medicines down 7% from April as govt caps ceiling prices</a></strong><br /><br />The affected lot has been manufactured by Hyderabad-based Gland Pharma and distributed in the US by Sun Pharmaceutical Industries, the USFDA stated. Sun Pharmaceutical Inc initiated the Class III nationwide recall (US) on March 29 this year.</p>.<p>As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences".</p>.<p>In a separate disclosure, the USFDA said the US-based arm of Hetero Labs is recalling a drug used to treat certain stomach and esophagus problems.</p>.<p>Hetero USA Inc is recalling 2,352 bottles of Pantoprazole Sodium delayed release tablets for "CGMP Deviations: Discoloration", the USFDA stated.</p>.<p>The affected lot was produced by Hetero Labs for New Jersey-based Camber Pharmaceuticals Inc, it added.</p>.<p>Hetero USA Inc initiated the Class II recall on March 14 this year.</p>.<p>As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.</p>.<p>The Indian pharmaceutical industry is the world's third-largest by volume and 14th-largest in terms of value. India exported pharmaceuticals worth Rs 1,75,040 crore in the financial year 2021-22, including bulk drugs/ drug intermediates.</p>.<p>The US is the world's largest market for pharmaceutical products.</p>
<p>Drug makers Sun Pharma and Hetero are recalling products in the US market for manufacturing issues, according to the US Food and Drug Administration (USFDA).</p>.<p>As per the US health regulator's latest Enforcement Report, the US-based arm of Sun Pharmaceutical Industries is recalling a generic drug indicated to raise blood pressure in adult patients with acute hypotension.</p>.<p>Princeton (New Jersey) based Sun Pharmaceutical Inc is recalling 16,450 vials of Norepinephrine Bitartrate Injection for "Failed Impurities/Degradation Specifications", it said.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/national/cost-of-651-essential-medicines-down-7-from-april-as-govt-caps-ceiling-prices-1206280.html" target="_blank">Cost of 651 essential medicines down 7% from April as govt caps ceiling prices</a></strong><br /><br />The affected lot has been manufactured by Hyderabad-based Gland Pharma and distributed in the US by Sun Pharmaceutical Industries, the USFDA stated. Sun Pharmaceutical Inc initiated the Class III nationwide recall (US) on March 29 this year.</p>.<p>As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences".</p>.<p>In a separate disclosure, the USFDA said the US-based arm of Hetero Labs is recalling a drug used to treat certain stomach and esophagus problems.</p>.<p>Hetero USA Inc is recalling 2,352 bottles of Pantoprazole Sodium delayed release tablets for "CGMP Deviations: Discoloration", the USFDA stated.</p>.<p>The affected lot was produced by Hetero Labs for New Jersey-based Camber Pharmaceuticals Inc, it added.</p>.<p>Hetero USA Inc initiated the Class II recall on March 14 this year.</p>.<p>As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.</p>.<p>The Indian pharmaceutical industry is the world's third-largest by volume and 14th-largest in terms of value. India exported pharmaceuticals worth Rs 1,75,040 crore in the financial year 2021-22, including bulk drugs/ drug intermediates.</p>.<p>The US is the world's largest market for pharmaceutical products.</p>